Angiotensin-Converting Enzyme Inhibitors

"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.

Descriptor ID	D000806
MeSH Number(s)	D27.505.519.389.745.085
Concept/Terms	Angiotensin-Converting Enzyme Inhibitors Angiotensin-Converting Enzyme Inhibitors Angiotensin Converting Enzyme Inhibitors Inhibitors, Kininase II Kininase II Antagonists Kininase II Inhibitors Angiotensin I-Converting Enzyme Inhibitors Angiotensin I Converting Enzyme Inhibitors Antagonists, Angiotensin-Converting Enzyme Antagonists, Angiotensin Converting Enzyme Antagonists, Kininase II Inhibitors, ACE ACE Inhibitors Inhibitors, Angiotensin-Converting Enzyme Enzyme Inhibitors, Angiotensin-Converting Inhibitors, Angiotensin Converting Enzyme Angiotensin-Converting Enzyme Antagonists Angiotensin Converting Enzyme Antagonists Enzyme Antagonists, Angiotensin-Converting

Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Protease Inhibitors [D27.505.519.389.745]
Angiotensin-Converting Enzyme Inhibitors [D27.505.519.389.745.085]

Below are MeSH descriptors whose meaning is related to "Angiotensin-Converting Enzyme Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".

Angiotensin-Converting Enzyme Inhibitors
Vasopeptidase Inhibitors

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications.

Bar chart showing 156 publications over 30 distinct years, with a maximum of 12 publications in 2003

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	2	1	3
1997	2	0	2
1998	2	0	2
1999	4	3	7
2000	2	2	4
2001	6	4	10
2002	2	1	3
2003	8	4	12
2004	3	2	5
2005	1	5	6
2006	2	4	6
2007	2	6	8
2008	5	4	9
2009	5	6	11
2010	1	5	6
2011	3	1	4
2012	0	1	1
2013	2	2	4
2014	2	4	6
2015	3	1	4
2016	0	3	3
2017	1	3	4
2018	2	0	2
2019	3	3	6
2020	4	2	6
2021	5	3	8
2022	1	7	8
2023	1	1	2
2024	1	2	3
2025	0	1	1

Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.

Qaseem A, Cooney TG, Etxeandia-Ikobaltzeta I, Wilt TJ, Harrod CS, Tice JA, Crandall CJ, Hicks LA, Cross JT, Fitterman N, Lewis J, Linsky AM, Maroto M, Miller MC, Obley AJ, Owens DK, Shekelle PG, Shamliyan T, Yost J. Prevention of Episodic Migraine Headache Using Pharmacologic Treatments in Outpatient Settings: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2025 Mar; 178(3):426-433.

View in: PubMed
Shoji S, Kaltenbach L, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Butler J, Allen LA, Lanfear DE, Thibodeau JT, Chapman BM, Oliver-McNeil SM, Felker GM, Pina IL, Granger CB, Hernandez AF, DeVore AD. Guideline-Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT-HF. J Am Heart Assoc. 2024 12 17; 13(24):e036998.

View in: PubMed
Fares J, El Fadel O, Zhao J, Li M, Sun J, Roman J, Loizidis G, Summer R. Mortality and Health Outcomes Among Patients With Sarcoidosis Treated With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Chest. 2025 03; 167(3):772-780.

View in: PubMed
Newman E, Kamanu C, Gibson G, Brailovsky Y. How to Optimize Goal-Directed Medical Therapy (GDMT) in Patients with Heart Failure. Curr Cardiol Rep. 2024 09; 26(9):995-1003.

View in: PubMed
Tito S, Manzano JMM, Ogunmola I, Prendergast A, Patel A, Casipit B, Cantu-Martinez O, Jarrett SA, Chiang B, Sarvottam K, Azmaiparashvili Z, Lo KB, Rangaswami J. Cardiovascular Outcomes After Angiotensin Converting Enzyme Inhibitor Induced Angioedema: A Retrospective Cohort Analysis. Am J Cardiol. 2023 10 15; 205:393-395.

View in: PubMed
An J, Zhou H, Ni L, Harrision TN, Wei R, Agiro A, Brahmbhatt YG, Oluwatosin Y, Schilling CG, Sim JJ. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes. Am J Nephrol. 2023; 54(7-8):258-267.

View in: PubMed
Derington CG, Bress AP, Moran AE, Weintraub WS, Herrick JS, Cushman WC, Kronish IM, Stults B, Shimbo D, Muntner P, Greene T, Bates JT, Chang TI, Katz LA, Rehman SU, Roumie CL, Tamariz L, King JB. Antihypertensive Medication Regimens Used in the Systolic Blood Pressure Intervention Trial. Hypertension. 2023 03; 80(3):590-597.

View in: PubMed
Weight N, Moledina S, Zoccai GB, Zaman S, Smith T, Siller-Matula J, Dafaalla M, Rashid M, Nolan J, Mamas MA. Impact of pre-existing vascular disease on clinical outcomes. Eur Heart J Qual Care Clin Outcomes. 2022 12 13; 9(1):64-75.

View in: PubMed
Moledina SM, Mannan F, Weight N, Alisiddiq Z, Elbadawi A, Elgendy IY, Fischman DL, Mamas MA. Impact of QRS Duration on Non-ST-Segment Elevation Myocardial Infarction (from a National Registry). Am J Cardiol. 2022 11 15; 183:1-7.

View in: PubMed
Gupta N, Settle L, Brown BR, Armaignac DL, Baram M, Perkins NE, Kaufman M, Melamed RR, Christie AB, Danesh VC, Denson JL, Cheruku SR, Boman K, Bansal V, Kumar VK, Walkey AJ, Domecq JP, Kashyap R, Aston CE. Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19. Crit Care Med. 2022 10 01; 50(10):e744-e758.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement